JMP Group is a holding company. Through its subsidiaries, the company is a capital markets firm. The company provides investment banking, sales and trading, and equity research services to corporate and institutional clients as well as alternative asset management products and services to institutional investors and individuals. In addition, the company manages and invests in corporate credit instruments through collateralized loan obligations and direct investments, and it serves as the investment advisor to a business development company. The company's investment banking provides capital raising services, mergers and acquisitions transaction services, and other advisory services to corporate clients.

Palatin Technologies is a biopharmaceutical company developing medicines that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The company's primary product, Vyleesi? is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder, characterized by low sexual desire that causes marked distress or interpersonal difficulty. The company's product development activities focus on melanocortin receptors, MC1r agonists, with potential to treat inflammatory and autoimmune diseases.